Gyre Therapeutics, Inc. SEC filings GYRE
Gyre Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Sep 10, 2013. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 4, 2026 | — |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 10, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2026 | Jun 10, 2026 |
| DEFA14A | Additional proxy material | Apr 21, 2025 | — |
| DEF 14A | Proxy statement | Apr 21, 2025 | Jun 4, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 12, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2024 | Jun 12, 2024 |
| DEFM14A | Form defm14a | Jul 20, 2023 | — |
| DEFA14A | Additional proxy material | Jun 20, 2023 | — |
| DEFA14A | Additional proxy material | May 5, 2023 | — |
| DEFA14A | Additional proxy material | Apr 7, 2023 | — |
| PREM14A | Filing | Mar 30, 2023 | Mar 30, 2023 |
| DEFA14A | Additional proxy material | Mar 30, 2023 | — |
| DEFA14A | Additional proxy material | Mar 21, 2023 | — |
| DEFA14A | Additional proxy material | Mar 2, 2023 | — |
| DEFA14A | Additional proxy material | Aug 10, 2022 | — |
| DEFA14A | Additional proxy material | Aug 4, 2022 | — |
| DEFA14A | Additional proxy material | Aug 3, 2022 | — |
| DEFA14A | Additional proxy material | Aug 1, 2022 | — |
| DEFA14A | Additional proxy material | Aug 1, 2022 | — |
| DEFA14A | Additional proxy material | Jul 29, 2022 | — |
| DEFA14A | Additional proxy material | Jul 19, 2022 | — |
| DEFA14A | Additional proxy material | Jul 6, 2022 | — |
| DEFA14A | Additional proxy material | Jun 29, 2022 | — |
| DEFA14A | Additional proxy material | Jun 28, 2022 | — |
| DEFA14A | Additional proxy material | Jun 9, 2022 | — |
| DEFA14A | Additional proxy material | May 20, 2021 | — |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 9, 2021 |
| DEFA14A | Additional proxy material | May 1, 2020 | — |
| DEF 14A | Proxy statement | May 1, 2020 | Jun 11, 2020 |
| DEFA14A | Additional proxy material | May 2, 2019 | — |
| DEF 14A | Proxy statement | May 2, 2019 | Jun 13, 2019 |
| DEF 14A | Proxy statement | May 11, 2018 | Jun 13, 2018 |
| DEF 14A | Proxy statement | May 18, 2017 | Jun 15, 2017 |
| DEF 14A | Proxy statement | Jan 12, 2017 | Feb 2, 2017 |
| PRE 14A | Preliminary proxy statement | Dec 30, 2016 | Dec 30, 2016 |
| DEF 14A | Proxy statement | Apr 25, 2016 | Jun 9, 2016 |
| DEF 14A | Proxy statement | Nov 23, 2015 | Dec 14, 2015 |
| DEFA14A | Additional proxy material | Apr 18, 2014 | — |
| DEF 14A | Proxy statement | Apr 18, 2014 | Jun 5, 2014 |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GYRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1124105
- Former names
- CATALYST BIOSCIENCES, INC. (until Oct 27, 2023); TARGACEPT INC (until Aug 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.